Venetoclax for paediatric acute myeloid leukaemia: a step forward
Mené sur 38 patients âgés de 2 à 22 ans et atteints d'une leucémie myéloïde aiguë réfractaire ou récidivante, cet essai de phase I évalue la dose maximale tolérée du vénétoclax en combinaison avec une chimiothérapie à hautes doses ou à doses standard de cytarabine avec ou sans idarubicine, puis évalue la proportion de patients ayant obtenu une rémission complète
In The Lancet Oncology, Seth E Karol and colleagues report the exciting results of a phase 1 trial combining venetoclax with low and high intensity chemotherapy for paediatric acute myeloid leukaemia. Venetoclax is a BCL-2 inhibitor that has been approved for induction therapy of acute myeloid leukaemia in older adults who are unfit for intensive chemotherapy. This new study is notable for several reasons. First, it is not only the first peer-reviewed publication evaluating the efficacy of venetoclax in a paediatric population, but also the first evaluation of the combination of venetoclax with intensive acute myeloid leukaemia chemotherapy. Thus, in addition to their implications for children, these results are also relevant for the much larger group of adults with acute myeloid leukaemia who are fit for intensive therapy. This study therefore continues the tradition of rigorous paediatric oncology research having an effect that exceeds the proportionally small number of children with cancer.
The Lancet Oncology , commentaire, 2019